The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by regulating expression of genes involved in apoptosis, cell cycle arrest and oxidative detoxification. Here, we demonstrate that cyclin-dependent kinase 1 (CDK1) specifically phosphorylates FOXO1 at serine 249 (S249) in vitro and in vivo. Coimmunoprecipitation assays demonstrate that both endogenous CDK1 and ectopically expressed CDK1 form a protein complex with FOXO1 in prostate cancer (PCa) cells. In vitro protein binding assays reveal that CDK1 interacts directly with FOXO1. Accordingly, overexpression of CDK1 inhibits the transcriptional activity of FOXO1 in PCa cells through S249 phosphorylation on FOXO1. Consistent with the roles of FOXO3a and FOXO4 (two other members of the FOXO family) in cell cycle regulation, forced expression of FOXO1 causes a delay in the transition from G2 to M phase. This effect is blocked completely by overexpression of CDK1 and cyclin B1. Ectopic expression of constitutively active CDK1 also inhibits FOXO1-induced apoptosis in PCa cells. Moreover, we demonstrate that the inhibitory effect of FOXO1 on Ras oncogene-induced colony formation in fibroblasts is diminished by overexpression of CDK1. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, our findings suggest that aberrant activation of CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival via phosphorylation and inhibition of FOXO1.
Introduction

O-class forkhead box (FOXO) proteins, which include FOXO1 (FKHR), FOXO3a (FLHRL1), FOXO4
(AFX) and FOXO6 in humans, belong to the superfamily of forkhead transcription factors (Greer and Brunet, 2005) . Emerging evidence suggests that FOXO transcription factors possess tumor suppressor functions by regulating expression of genes involved in apoptosis, cell proliferation and genotoxic/oxidative stresses (Huang and Tindall, 2007) . Activation of FOXO proteins upregulates proapoptotic genes, such as Fas ligand (FasL), Bim and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (Brunet et al., 1999; Dijkers et al., 2000; Modur et al., 2002; Gilley et al., 2003) . FOXO proteins also transcriptionally regulate expression of an array of genes that encode proteins functioning at various cell cycle checkpoints. FOXO proteins induce cell cycle arrest at G1 by upregulating cyclin-dependent kinase (CDK) inhibitors p27 KIP1 , p21 WAF1 and the retinoblastoma protein-related protein p130, and by downregulating cyclins D1 and D2 Nakamura et al., 2000; Kops et al., 2002; Ramaswamy et al., 2002; Schmidt et al., 2002; Seoane et al., 2004) . Expression of growth arrest and DNA-damaging-inducible protein 45a (Gadd45a), a protein with a critical function in the G2-to-M transition, is regulated by FOXO3a and FOXO4 (Furukawa-Hibi et al., 2002; Tran et al., 2002) , suggesting a role of FOXO proteins in the regulation of mitosis.
The importance of FOXO proteins in tumor suppression is further reflected by the fact that these proteins are often dysregulated either at the genomic level or by aberrant oncogenic signaling pathways. FOXO1, FOXO3a and FOXO4 genes are all affected by chromosomal translocations detected in solid tumors and leukemias (Galili et al., 1993; Borkhardt et al., 1997; Hillion et al., 1997) . In addition, the activity of FOXO factors is tightly regulated by post-translational modifications, including phosphorylation, acetylation and ubiquitylation. A number of inhibitory phosphorylation sites have been identified in FOXO proteins. For example, Akt inhibits the tumor suppressor function of FOXO proteins by promoting phosphorylation of these proteins in multiple sites (Biggs et al., 1999; Brunet et al., 1999; Kops et al., 1999; Rena et al., 1999; Tang et al., 1999) . Akt phosphorylation not only causes nuclear export of FOXO proteins but also induces polyubiquitylation and proteasome degradation of FOXO1 and FOXO3a (Matsuzaki et al., 2003; Plas and Thompson, 2003; Aoki et al., 2004) . Aktphosphorylated FOXO1 interacts with Skp2, the substrate-binding component of the Skp1/culin 1/F-box protein (SCF Skp2 ) E3 ligase complex and is targeted for ubiquitin-dependent proteasome degradation (Huang et al., 2005) . Phosphorylation of FOXO proteins by other kinases, including serum-and glucocorticoidinducible kinases, protein kinase CK1, dual-specificity tyrosine-phosphorylated and regulated kinase 1A, and IkB kinase, also inhibits the activity of FOXO proteins (Brunet et al., 2001; Woods et al., 2001; Rena et al., 2002; Hu et al., 2004) . Our recent studies demonstrate that CDK2, which is a kinase thought to play a critical role in the G1-to-S transition, specifically phosphorylates FOXO1 at serine 249 (S249). Phosphorylation at this site leads to the nuclear exportation and subsequent transcriptional inhibition of FOXO1 (Huang et al., 2006) .
The cell division cycle is driven by the sequential activation of CDK complexes. CDK2 and other G1 CDKs, including CDK4 and CDK6, along with their associated cyclins, are known to be involved in the G1/S transition (Sherr and Roberts, 2004) . The CDK1/cyclin B kinase complex is the main regulator of the G2-to-M transition. The cyclin B1/CDK1 kinase complex is believed to promote cell cycle transitions at late G2 and mitosis by phosphorylating substrates and triggering reorganization of the nuclear envelope, spindle apparatus and actin cytoskeleton. Interestingly, a recent mouse genetic study demonstrates that mammalian CDK1 is sufficient to drive the cell cycle in the absence of G1 CDKs (Santamaria et al., 2007) , highlighting an important role of CDK1 in regulation of the cell cycle. Indeed, cell cycle regulatory proteins are often dysregulated in human cancers. In this report, we demonstrate that CDK1 binds to and phosphorylates FOXO1 at S249 in vitro and in vivo, thereby abolishing the inhibitory effect of FOXO1 on cell growth and survival. Thus, our findings reveal a novel mechanism by which CDK1 regulates cell proliferation and survival.
Results
CDK1 phosphorylates FOXO1 at S249 in vitro
We demonstrated previously that CDK2 phosphorylates FOXO1 at S249 in vitro and in vivo (Huang et al., 2006) . We also demonstrated that S249 phosphorylation is low during the G1 phase and increased markedly in the S phase. As FOXO1 S249 phosphorylation was also observed in cells in G2/M phases (Huang et al., 2006) , where CDK1 is highly active, we sought to determine whether FOXO1 is phosphorylated by CDK1. First, we performed in vitro kinase assays using a series of glutathione S-transferase (GST)-FOXO1 recombinant proteins ( Figure 1a and lower panel in Figure 1b ) as substrates. As demonstrated in Figure 1b (upper panel), endogenous CDK1 immunoprecipitated from LNCaP prostate cancer (PCa) cells phosphorylates the FO1-2 and FO1-3 GST-FOXO1 recombinant proteins. The amount of CDK1 phosphorylation in FOXO1 was greater than the phosphorylation of histone H1, a known substrate of CDK1 (Figure 1b, upper panel) . No phosphorylation of the control GST protein was detected under the same conditions. To rule out the possibility that FOXO1 phosphorylation is mediated by the other kinase(s) that may coimmunoprecipitate with CDK1, we performed in vitro kinase assays using the reconstituted CDK1/cyclin B1 kinase complex, and obtained similar results as seen with the endogenous CDK1 immunoprecipitated from cells ( Figure 1c ). These data indicate that CDK1 can phosphorylate FOXO1 in vitro. Next, we sought to determine which residue in FOXO1 can be phosphorylated by CDK1. CDKs often recognize and phosphorylate the serine/ threonine-proline (S/T-P) motif. There is only one such motif (S249/P250) present in FO1-2, which is shared by both FO1-2 and FO1-3. In addition, there are seven more such motifs found in FO1-3 (Figure 1d ). To determine which S/T-P motif in FOXO1 is phosphorylated by CDK1, we generated three truncated GST-FOXO1 recombinant proteins from FO1-3 ( Figure 1d ). Kinase assays demonstrated that CDK1 phosphorylates FO1-6, but not FO1-7 or FO1-8 ( Figure 1e , left panel). As shown in Figure 1d , there is only one S/T-P motif (S249/P250) present in FO1-6 and mutation of this residue to alanine (S249A) completely abolished CDK1-mediated phosphorylation of FO1-3 ( Figure 1e , right panel). S249A mutation also abolished CDK1-mediated phosphorylation of FO1-2 (data not shown). Collectively, these results suggest that CDK1 specifically phosphorylates FOXO1 at S249 in vitro.
CDK1 phosphorylates FOXO1 at S249 in vivo To determine whether CDK1 phosphorylates FOXO1 at S249 in vivo, wild-type and S249A-mutated FLAG-FOXO1 were transfected into LNCaP cells and phosphorylation of FOXO1 was examined by immunoblotting with the phospho-specific antibody against phospho-S249. As shown in Figure 2a , wild-type (lane 4) but not S249A mutant FOXO1 (lane 2) was readily phosphorylated at S249. Consistently, forced expression of constitutively active CDK1 increases S249 phosphorylation of the wild-type FOXO1 but not the S249A mutant (Figure 2a , lane 5 versus lane 3). As shown previously (Huang et al., 2006) , ectopic expression of constitutively active CDK2 increases FOXO1 phosphorylation at this residue ( Figure 2a, lane 1) . Similar to CDK2, silencing of CDK1 using a pool of gene-specific small interfering RNAs (siRNAs) resulted in a decrease in FOXO1 phosphorylation (Figure 2b ). FOXO1 phosphorylation was largely diminished in cells where both CDK1 and CDK2 genes were silenced (Figure 2b ). These observations indicate that in addition to CDK2 (Huang et al., 2006) , CDK1 can also phosphorylate FOXO1 at S249 in cells.
CDK1 interacts with FOXO1 in vivo and in vitro Next, we sought to determine whether CDK1 interacts with FOXO1 in cells. LNCaP cells were transfected with FLAG-tagged FOXO1 and V5-tagged CDK1. At 48 h after transfection, cells were collected and cell lysates were subjected to immunoprecipitation with either an anti-FLAG antibody or an anti-V5 antibody. As demonstrated in Figure, V5 -tagged CDK1 was detected in the protein complex immunoprecipitated by the anti-FLAG antibody. Reciprocally, FLAG-tagged FOXO1 was detected in the protein complex immunoprecipitated by the anti-V5 antibody (Figure 3b ). We also examined the interaction between endogenous FOXO1 and CDK1 in LNCaP cells. As demonstrated in Figure 3c , endogenous CDK1 was readily immunoprecipitated by an antibody against CDK1. Notably, FOXO1 proteins were detected in the protein complex immunoprecipitated by the anti-CDK1 antibody (Figure 3c ). These data suggest that CDK1 interacts with FOXO1 in vivo. To determine whether CDK1 interacts directly with FOXO1 and to map the region(s) in FOXO1 that are required for this interaction, we performed in vitro protein binding assays using Figure 3d (upper panel), a strong interaction is detected between CDK1 and FO1-3 (amino acids 211-419 of FOXO1). There also appears to be a weak interaction between CDK1 and FO1-2 (amino acids 149-267 of FOXO1), albeit the detected band migrates slightly faster than expected (Figure 3d , upper panel) and the result was reproducible. These data suggest that CDK1 interacts directly with FOXO1.
CDK1 inhibits the transcriptional activity of FOXO1 As FOXO1 functions primarily as a transcription factor (Huang and Tindall, 2007) , we sought to determine whether the transcriptional activity of FOXO1 is affected by CDK1. As demonstrated in Figures 4a and Figure 4a ). To determine whether inhibition of FOXO1 by CDK1 is mediated through phosphorylation, a number of phosphorylation-resistant mutants of FOXO1 were generated, and their transcriptional activities were examined in LNCaP cells in which Akt is constitutively active due to loss of phosphatase and tensin homologue deleted on chromosome ten (PTEN) (Wu et al., 1998) . As expected, without overexpression of CDK1 and cyclin B1, triple mutations of the three Akt phosphorylation sites (FOXO1-A3) resulted in a high basal activity of FOXO1 in LNCaP cells ( Figure 4c ). However, the activity of the triple mutant was inhibited by the expression of CDK1 and cyclin B1 (Figure 4c ). Similarly, restored expression of PTEN increased the transcriptional activity of FOXO1 in LNCaP cells and overexpression of CDK1 and cyclin B1 mitigated PTEN-induced increase in FOXO1 transcriptional activity (Figure 4d ). These data suggest that CDK1 inhibits the transcriptional activity of FOXO1 in an Akt-independent manner. Moreover, introduction of the S249A mutation that makes FOXO1 impervious to the CDK1-mediated phosphorylation (Figure 2a ) resulted in a higher transcriptional activity than FOXO1-A3 ( Figure 4c ). Importantly, the inhibitory effect of CDK1 on FOXO1-A3 was abrogated by the S249A mutation ( Figure 4c ). Together, these data suggest that CDK1-induced inhibition of transcriptional activity of FOXO1 is mediated primarily by the phosphorylation of S249. In line with these findings, silencing of endogenous CDK1 and/or CDK2 increased the activity of the FOXO1 reporter gene in LNCaP cells (Figure 4e ).
CDK1 overcomes FOXO1-induced delay in the G2-to-M transition
Previous studies demonstrated that ectopic expression of active FOXO3a and FOXO4 induces increased Gadd45a expression and a delay in G2-to-M transition (Furukawa-Hibi et al., 2002; Tran et al., 2002) . We sought to determine whether CDK1 regulates G2-to-M transition via inhibition of FOXO1. To this end, we examined cell cycle transition after synchronization by treating cells with the S-phase-blocking agent aphidicolin. NIH 3T3 cells were transfected with an expression vector for green fluorescence protein (GFP) and various expression constructs as indicated in Figure 5a . Cells were treated with 1 mg/ml aphidicolin for 24 h followed by phosphate-buffered saline washes to release the cells from the S-phase blockage. Cells were collected at different time points (3, 5, 7 and 9 h), fixed, stained with propidium iodide and subjected to fluorescence-activated cell sorting (FACS) analysis. As demonstrated in Figure 5a , the majority of the cells transfected with the empty vector (pcDNA3.1) were in G1 and S phases 3 h after release from the S-phase blockage. Approximately 20% of cells were in G2/M phases. Similar results were obtained in cells transfected with FOXO1-A3 at this time point. In contrast, approximately 45% of cells transfected with CDK1-AF were in G2/M phases at 3 h after release (Figure 5a ). Although the majority of cells transfected with either empty vector or CDK1-AF were in G1 phase 9 h after release, the majority (approximately Immunoprecipitants were analysed by western blot using antibodies against S249-p, FOXO1, V5 tag and cyclin B1. (b) LNCaP cells transfected with FLAG-FOXO1 expression vector in combination with control siRNA, CDK1 siRNA and/or CDK2 siRNA. At 72 h after transfection, cells were harvested and cell lysates were subjected to immunoprecipitation and western blot analysis as described in panel a. Similar results were obtained from three independent experiments. CDK, cyclin-dependent kinase; FOXO, O-class forkhead box; S249, serine 249; siRNA, small interfering RNA. 60%) of cells transfected with FOXO1-A3 were in G2/ M phases (Figure 5a ). This effect was largely inhibited by co-transfection with CDK1-AF ( Figure 5a ). Next, we examined the effect of FOXO1 on mitosis by staining cells with antibodies against histone H3 phosphorylation at serine 10 (H3-p), a known mitotic marker (Tran et al., 2002) . As shown in Figure 5b , approximately 40% of cells transfected with empty vector were H3-p positive at 7 h after release from aphidicolin treatment. At this time point, fewer cells transfected with CDK1-AF were H3-p positive than cells transfected with empty vector (Figure 5b ), which is consistent with the FACS data that expression of CDK1-AF accelerated cell cycle progression ( Figure 5a , the first column versus the third column). Importantly, H3-p-positive cells were largely reduced by ectopic expression of FOXO1-A3 (Figure 5b) , suggesting an inhibitory role of FOXO1 in mitosis. This inhibitory effect was abrogated by co-transfection with CDK1-AF (Figure 5b) . Expression of FOXO1-A3/S249A also reduced the percentage of cells in mitosis (Figure 5b) . However, forced expression of CDK1-AF did not override the FOXO1-A3/S249A-mediated inhibition of mitosis. Results from a representative experiment are shown in Figure 5c . In line with these findings, forced expression of FOXO1-A3 increased the levels of Gadd45a protein expression in NIH 3T3 cells (Figure 5b, lower panel) . This effect was inhibited in cells that were co-transfected with CDK1-AF and cyclin B1 (Figure 5b ). However, FOXO1-A3/ S249A-induced expression of Gadd45a was not affected and/or FOXO1 on G2/M progression. NIH 3T3 cells were transfected with plasmids as indicated and plated in culture media containing 1 mg/ml aphidicolin. At 24 h after aphidicolin treatment, cells were released by culturing in aphidicolin-free media. At different time points as indicated, cells were harvested, fixed and stained with propidium iodide (PI), and FACS analysis was performed. Quantification of a representative experiment is shown in bar graphs. (b) Upper panel: mitosis marker (histone H3 phosphorylation at Ser10) analysis of effect of expression of CDK1 and/or FOXO1 on G2-to-M transition. NIH 3T3 cells were transfected with plasmids as indicated and plated in media containing 1 mg/ml aphidicolin. At 24 h after treatment, aphidicolin was washed out to release the cell cycle blockage. At 7 h after release, immunofluorescence chemistry experiments were performed using the anti-FLAG antibody (green) or GFP to detect cells expressing FLAG-FOXO1 or control cells expressing GFP, respectively, and the anti-phospho-histone H3 Ser10 antibody (red) to detect mitotic cells. Taken together, these data suggest that FOXO1 is a critical negative regulator of the G2-to-M transition and that activation of CDK1 overcomes FOXO1-mediated inhibition on mitosis via phosphorylation of FOXO1 at S249. (Figure 6d) . Finally, the longterm effect of CDK1 phosphorylation of FOXO1 on cell growth and survival was evident in colony formation assays (Supplementary Information). Together, these data suggest that overexpressed CDK1 blocks FOXO1-induced death of LNCaP PCa cells via phosphorylation of FOXO1 at S249.
Discussion
Genetic and biochemical studies demonstrate that FOXO proteins possess a tumor suppressor function that appears to be evolutionally conserved (Huang et al., 2006; Pinkston et al., 2006; Matsuoka et al., 2007; Paik et al., 2007; Pinkston-Gosse and Kenyon, 2007) . The importance of FOXO proteins in human cancer is further evident in the fact that the functions of these proteins are often inhibited by oncogenic proteins such as Akt, IkB kinase and Skp2 (Brunet et al., 1999; Hu et al., 2004; Huang et al., 2005) . In an effort of understanding the mechanism by which FOXO1 activity is regulated, we demonstrated previously that CDK2 interacts with and inhibits FOXO1 via phosphorylation of FOXO1 at S249 (Huang et al., 2006) . In this study, we provide evidence that CDK1 also interacts with and specifically phosphorylates FOXO1 at S249, and accordingly, inhibits the transcriptional activity of FOXO1. In addition, we demonstrate an inhibitory role of FOXO1 in mitosis, which is overcome by CDK1 phosphorylation of FOXO1 at S249. We further demonstrate that CDK1 phosphorylation of FOXO1 not only abolishes FOXO1-induced cell death but also overrides FOXO1-mediated inhibition of growth and survival of oncogene-transformed cells. Thus, inhibition of FOXO1 by CDK1 represents a novel mechanism that may play an important role in tumorigenesis. Mouse embryos lacking all interphase CDKs (CDK2, CDK3, CDK4 and CDK6) undergo organogenesis and develop to midgestation (Santamaria et al., 2007) . In contrast, embryos fail to develop to the morula and blastocyst stages in the absence of CDK1 (Santamaria et al., 2007) , indicating that CDK1 ablation leads to a lethal phenotype. Analogously, generation of stable CDK1-depleted PCa cells has been unsuccessful . Thus, CDK1 appears to be not only important for cell proliferation but also critical for cell survival. We demonstrate that silencing of endogenous CDK1 results in a decrease in the phosphorylation of FOXO1 at S249 and an increase in the transcriptional activity of FOXO1 in PCa cells. It is likely that depletion of CDK1 leads to cell death by activating the proapoptotic function of FOXO1. Further studies on the role of CDK1 phosphorylation of FOXO1 in the survival of CDK1-null embryo or CDK1-null cells are warranted.
Studies with clinical cancer specimens implicate that CDK1 may play an important role in human cancers. Aberrant expression of CDK1 and cyclin B1 has been described in a number of primary tumors, including PCa (Kallakury et al., 1997; Soria et al., 2000) . Several groups have shown previously that expression of CDK1 is increased in human PCa relative to normal prostatic tissues (Mashal et al., 1996; Kallakury et al., 1997 Kallakury et al., , 1998 . Cdc25C, an upstream activator of CDK1, is found not only upregulated in PCa but is also present exclusively in its active form (Ozen and Ittmann, 2005) . Cdc25B, another activator of CDK1, is overexpressed in PCa. Moreover, loss-of-function mutations of the Chk2 (also known Chek2) gene, an upstream negative regulator of CDK1, have been detected in PCa patients (Dong et al., 2003; Wu et al., 2006) . In addition, cyclins B1 and B2 are found overexpressed in the progression of PCa (Maddison et al., 2004; Stanbrough et al., 2006) . We demonstrate in this study that overexpression of CDK1 and cyclin B1 markedly inhibits the transcriptional activity of FOXO1. Accordingly, the tumor suppressor functions of FOXO1, which include the inhibitory effect of FOXO1 on the G2-to-M transition, apoptosis and growth of the Ras-transformed cells, were abrogated by overexpression of CDK1 and cyclin B1. In contrast, no inhibitory effect of CDK1 and cyclin B1 was observed on the FOXO1 mutant that is resistant to S249 phosphorylation. Thus, our findings suggest that overexpression of CDK1 and cyclin B1 in human tumors may lead to the loss of function of FOXO1 because of S249 phosphorylation, thereby promoting cancer development and progression.
Increased activity of CDK1 in human cancers makes it a potential target for cancer therapy. Currently, there are a number of ongoing clinical trials using inhibitors of CDK1 and other CDKs, including flavopiridol, UCN-01, CYC202 (racemic roscovitine) and MMS-387032 (Knockaert et al., 2002) . More potent and selective small-molecule CDK1 inhibitors, such as purvalanol, have been developed (Gray et al., 1998; Goga et al., 2007) . Purvalanol treatment of Mycoverexpressed tumors induces rapid apoptosis by reducing the levels of the inhibitor of apoptosis survivin (Goga et al., 2007) . It is worth noting that purvalanol induces apoptosis in approximately 50% of cells, whereas silencing of survivin leads to apoptosis in approximately 20% of cells. This finding suggests that survivin-independent mechanisms also contribute to the cell death caused by CDK1 inhibition. Indeed, expression of Bim, a known target gene of FOXO proteins (Dijkers et al., 2000; Stahl et al., 2002; Gilley et al., 2003) , has been implicated in MYC-sensitized cell death (Green and Evan, 2002) . We demonstrated previously that treatment with the CDK inhibitor roscovitine increases the expression of Bim in LNCaP PCa cells (Huang et al., 2006) . We demonstrate in this study that forced expression of active FOXO1 results in an increase in the level of Bim protein and that overexpression of CDK1 overrides FOXO1-induced expression of Bim. Thus, it would be of great value to assess the role, if any, of FOXO1 S249 phosphorylation in the anticancer effect of CDK inhibitors that are currently being employed in clinical trials.
In summary, we demonstrate that CDK1 specifically phosphorylates FOXO1 at S249, and accordingly, leads to the loss of transcriptional activity of FOXO1. We also demonstrate that CDK1 phosphorylation of FOXO1 not only abolishes FOXO1-induced delay in the G2-to-M transition but also mitigates FOXO1-induced apoptosis in PCa cells and long-term growth and survival of fibroblasts transformed by oncogene Ras. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, CDK1-mediated inhibition of FOXO1 may very likely contribute to tumorigenesis and therapy resistance in human cancer.
Materials and methods
Plasmids and siRNAs
Plasmids for FLAG-tagged wild-type FOXO1 and Akt phosphorylation-resistant mutant of FOXO1 (FOXO1-WT and FOXO1-A3, originally named as FKHR-WT and FKHR-AAA, where the three Akt phosphorylation sites Thr24, Ser256 and Ser319 were converted to alanine) and the luciferase reporter construct, 3xIRS, which contains three copies of the FOXO response element in the promoter of the IGFBP1 gene, were kindly provided by KL Guan (Tang et al., 1999) . Plasmids for amino-acid substitution mutant of FOXO1-A3/S249A were generated by PCR-based mutagenesis (Stratagene, La Jolla, CA, USA). The V5-tagged expression vector of CDK2 was described previously (Huang et al., 2006) . Mammalian expression vectors of CDK1 and cyclin B1 were kindly provided by H Piwnica-Worms (Parker and PiwnicaWorms, 1992) , and were subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). The V5-tagged expression vector of CDK1 was generated in the pcDNA3.1D/V5-His using PCR. An active mutant of CDK1, CDK1-AF, was generated by converting Thr14 and Tyr15 to alanine and phenylalanine, respectively, via PCR-based mutagenesis (Stratagene). Expression vector for H-RasG12 V was kindly provided by R Urrutia (Fernandez-Zapico et al., 2003) . Constructs for GST-FOXO1 recombinant proteins were described previously (Huang et al., 2006) . Amino-acid substitution mutants of GST-FOXO1 were generated by PCR-based mutagenesis (Stratagene). Purified recombinant GST-CDK1, GST-cyclin B and histone H1 were purchased from Cell Signaling Technology (Danvers, MA, USA). The pEGFP vector was purchased from BD Biosciences (Mountain View, CA, USA) (Clontech). A pool of siRNAs for the human CDK1 and CDK2 gene and nonspecific control siRNAs were purchased from Dharmacon, Lafayette, CO, USA.
Antibodies and chemicals
A polyclonal antibody against phosphorylated S249 of FOXO1 (S249-p) was raised by immunizing rabbits with the phosphorylated peptide NPEGGKSGKpSPRRRAAS, and purified over a peptide-affinity column as described (Huang et al., 2006) . Other protein-specific antibodies were as follows: anti-FOXO1, anti-CDK1, anti-cyclinB1, anti-PARP, anti-Ras (Cell Signaling Technology); anti-CDK2 polyclonal (M2), anti-Gadd45a (H-165) polyclonal, anti-Erk2 monoclonal (Santa Cruz Biotechnology, Carlsbad, CA, USA); anti-V5 (Invitrogen); anti-FLAG (M2) (Sigma, St Louis, MO, USA) and anti-phospho-histone H3 at serine 10 (H3-p) (Millipore, Chicago, IL, USA). In vitro kinase assay buffer was purchased from Cell Signaling Technology; crystal violet, RNase A, aphidicolin and propidium iodide were obtained from Sigma-Aldrich, St Louis, MO, USA.
Cell culture, transfection, luciferase reporter assay and ChIP assay The PCa cell line LNCaP (purchased from the American Type Culture Collection, Manassas, VA, USA) was cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. NIH 3T3 cells were maintained in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were maintained at 37 1C and 5% CO 2 . Transfections were performed by electroporation using an Electro Square Porator ECM 830 (BTX). Approximately 75-90% transfection efficiencies were routinely achieved. Luciferase reporter assays were performed as described (Huang et al., 2006) . ChIP assays were performed as described (Huang et al., 2004b) . The forward primer 5 0 -CG GTTCGCTGCGTTCC-3 0 and reverse primer 5 0 -CGTC TCCGCTCGCACG-3 0 were designed based on the genomic sequence of the promoter of human Bim gene, which flanks the forkhead response element, GTAAACAC, characterized previously (Gilley et al., 2003) . PCR amplification was performed with 34 cycles of 94 1C for 30 s, 62 1C for 30 s and 72 1C for 45 s. The PCR products were analysed by 2% agarose gels and stained with ethidium bromide.
Immunoprecipitation, western blot, immunofluorescence chemistry and confocal microscopy Protein immunoprecipitations were carried out using an immunoprecipitation kit (Roche Applied Science, Indianapolis, IN, USA) as described (Huang et al., 2006) , and western blot was performed as described (Huang et al., 2001) . Immunofluorescence chemistry and confocal microscopy were performed as described (Huang et al., 2004a) .
Cell cycle analysis by flow cytometry NIH 3T3 cells were transfected or co-transfected with indicated plasmids and seeded in dishes with the medium containing 1 mg/ml aphidicolin. Twenty-four hours after incubation, cells were released from aphidicolin-mediated S-phase blockage by washing cells with 1 Â phosphatebuffered saline. At different time points, cells were collected and washed with 1 Â phosphate-buffered saline. After fixation with 70% ethanol, cells were washed twice with 1 Â phosphate-buffered saline and stained with a solution containing 20 mg/ml propidium iodide and 50 mg/ml RNase A. Cells were incubated for 30 min at the room temperature and cell cycle profiles were determined by flow cytometry using a FACScan (Becton-Dickinson, San Jose, CA, USA).
Colony formation assay
Colony forming assays were performed as described (Fernandez-Zapico et al., 2003) . Briefly, NIH 3T3 cells were transfected with the indicated plasmids. Approximately 1000 cells were seeded in 100-mm tissue culture dishes. Transfected cells were selected by adding G418 at a final concentration of 400 mg/ml. Two weeks after selection, colonies were fixed and stained with crystal violet. Colonies with one hundred or more cells were counted. Each group was assayed in triplicate and experiments were repeated three times.
In vitro kinase assay Kinase assays were carried out in the presence of [g-32 P]ATP by using an in vitro kinase buffer system obtained from Cell Signaling Technology as described (Huang et al., 2006) . Endogenous CDK1 immunoprecipitated from LNCaP cells or reconstituted CDK1 and cyclin B1 complexes obtained from Cell Signaling Technology were incubated with various substrates at 30 1C. Thirty minutes after reaction, proteins were subjected to SDS-polyacrylamide gel electrophoresis and autography.
Statistics
Experiments were carried out with three or four replicates. Statistical analyses were performed by Student's t-test. Values of Po0.05 are considered significant.
